Treatment strategies for myasthenia gravis

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 8, 2009, Pages 1329-1342

  Díaz Manera, Jordi ^a   Rojas García, Ricard ^a   Illa, Isabel ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Immunosuppressors; Intravenous immunoglobulins; Myasthenia gravis; Treatment

Indexed keywords

AZATHIOPRINE; CHOLINESTERASE INHIBITOR; CORTICOTROPIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; EDROPHONIUM; FOLIC ACID; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEOSTIGMINE; PLACEBO; PREDNISOLONE; PREDNISONE; PYRIDOSTIGMINE; RITUXIMAB; STEROID; TACROLIMUS;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACNE; ALOPECIA; AMENORRHEA; ANAPHYLAXIS; ARTERY THROMBOSIS; ASEPTIC MENINGITIS; BEHAVIOR CHANGE; BONE MARROW SUPPRESSION; BORBORYGMI; BRADYCARDIA; BRONCHOSPASM; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM VASCULITIS; CHILL; CLINICAL TRIAL; CONVULSION; CORTICOSTEROID INDUCED OSTEOPOROSIS; CREATININE BLOOD LEVEL; CYSTITIS; CYTOPENIA; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; EDEMA; ERYTHEMA; FATIGUE; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GLAUCOMA; HALLUCINATION; HEART ARRHYTHMIA; HEART INFARCTION; HEART RHYTHM; HEMORRHAGIC CYSTITIS; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPERURICEMIA; INSOMNIA; IRRITABILITY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TOXICITY; LOW DRUG DOSE; LUNG EMBOLISM; LUNG FIBROSIS; LUPUS VULGARIS; MOON FACE; MORNING DOSAGE; MORTALITY; MUCOSA INFLAMMATION; MUSCLE DISEASE; MUSCLE TWITCH; MUSCULAR FASCICULATION; MYALGIA; MYASTHENIA GRAVIS; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; OLIGOSPERMIA; OSTEOPOROSIS; PANCREATITIS; PLASMAPHERESIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; PSYCHOSIS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REMISSION; REPEATED DRUG DOSE; RETINA ARTERY OCCLUSION; RETINA VEIN OCCLUSION; REVIEW; SALIVATION; SIDE EFFECT; SKIN; SKIN MANIFESTATION; STROKE; TERATOGENICITY; THYMECTOMY; TREMOR; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VASCULITIS; VEIN THROMBOSIS; VIRUS INFECTION; WEAKNESS; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; MYASTHENIA GRAVIS; THYMECTOMY; YOUNG ADULT;

EID: 67649703557     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560902950619     Document Type: Review

References (109)

1. Keesey JC. Clinical evaluation and management of myasthenia gravis. Muscle Nerve 2004;29(4):484-505 (Pubitemid 38451340)
2. Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet 2001;357(9274):2122-8 •• An extraordinary review about MG, from clinical symptoms to treatment.
3. Howard JF, Sanders DB. The management of patients with myasthenia gravis. In: Alburquerque, Eldefrawi AT, editors, Myasthenia gravis. London, New York: Chapman and Hall, 1983. p. 457-489
4. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of America. Neurology 2000;55:16-23 •• This paper describes the most frequently used clinical classification of MG, and also the post-therapeutic status and the Quantitative Myasthenia Gravis Score (QMG).
5. McConville J, Farrugia ME, Beeson D, et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 2004;55:580-4 •• This paper demonstrates that AchR-ab are predominantly IgG1 and IgG3, while MuSk-ab are IgG4.
6. Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest 2006;116(11):2843-54 • An outstanding review about MG's physiopathology.
7. Sahashi K, Engel AG, Lambert EH, nd Howard FM Jr. Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis. J Neuropathol Exp Neurol 1980;39:160-172
8. Hoch W, McConville J, Helms S, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7:365-68 •• The first description of MuSk antibodies. (Pubitemid 32224355)
9. Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003;126(10):2304-2311 (Pubitemid 37432373)
10. Sanders DB, El-Salem K, Massey JM, et al. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003;60(12):1978-1980 (Pubitemid 36736017)
11. Illa I, Diaz-Manera JA, Juarez C, et al. Seronegative myasthenia gravis and antiMuSK positive antibodies: description of Spanish series. Med Clin (Barc) 2005;125(3):100-102 (Pubitemid 41044282)
12. Wolfe GI, Oh SJ. Clinical phenotype of muscle-specific tyrosine kinase-antibody-positive myasthenia gravis. Ann NY Acad Sci 2008;1132:71-75 (Pubitemid 351841348)
13. Evoli A, Bianchi MR, Riso R, et al. Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann NY Acad Sci 2008;1132:76-83 (Pubitemid 351841355)
14. Engel AG, Lambert EH, Santa T. Study of long term anticholinesterase therapy. Neurology 1973;23:1273-1281
15. Newsom-Davis J. Therapy in myasthenia gravis and Lambert-Eaton Myasthenic syndrome. Semin Neurol 2003;23:191-8 •• An important review about treatment of MG, describing the studies performed and also the personal recommendations of Dr Newsom-Davis.
16. Evoli A, Batocchi AP, Minisci C, et al. Therapeutic options in ocular myasthenia gravis. Neuromuscul Disord 2001;11:208-216 (Pubitemid 32201147)
17. Papatestas AE, Alpert LJ, Osserman KE, et al. Studies in myasthenia gravis. Effects of thymectomy. Results on 185 patients with non-thymoma and thymomathous myasthenia gravis. Am J Med 1971;50:465-474
18. Gronseth G, Barohn RJ. Practice parameter: thymectomy for autoinmune myasthenia gravis (an evidence-based review): report of the quality standards subcommittee of the American academy of neurology. Neurology 2000;55:7-15 •• A metaanalysis of response to treatment of 21 cohorts of non-thymomatous patients. (Pubitemid 30460990)
19. Newsom-Davis J, Cutter G, Wolfe GI, et al. Status of the thymectomy trial for nonthymomatous myasthenia gravis patients receiving prednisone. Ann NY Acad Sci 2008;1132:344-347 (Pubitemid 351841357)
20. Leite MI, Ströbel P, Jones M, et al. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol 2005;57:444-8 • First description of thymic alterations in MuSK patients.
21. Sonett JR, Jaretzki A 3rd. Thymectomy for nonthymomatous myasthenia gravis: a critical analysis. Ann NY Acad Sci 2008;1132:315-328
22. Nieto JP, Robledo JP, Pajuelo MC, et al. Prognostic factors for myasthenia gravis treated by thymectomy: review of 61 cases. Ann Thor Surg 1999;67:1568-1571 (Pubitemid 29301293)
23. Wright CD. Management of thymomas. Crit Rev Oncol Hematol 2007;65:109-20 •• A notable review about the therapeutic management of thymomas.
24. Kesler KA, Wright CD, Loehrer PJS. Thymoma: current medical and surgical management. Semin Neurol 2004;24:63-73 (Pubitemid 38823780)
25. Tindall RS. Humoral immunityin myasthenia gravis: effect of steroids and thymectomy. Neurolog 1980;30:554-557 (Pubitemid 10112818)
26. Hohlfeld R, Dalakas M. Basic principles of immunotherapy for neurologic diseases. Semin Neurol 2003;23:121-31 •• A commendable revision of immunosuppressors and their indications in neurologic diseases.
27. Taylor AL, Watson CJE, Bradley A. Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol 2005;56:23-46 • A good review about mechanism of function of inmunosuppressors.
28. Warmolts JR, Genkins G. Benefit from alternate day prednisone in myasthenia gravis. N Engl J Med 1972;286:17-20
29. Mount FW. Corticotropin in treatment of ocular myasthenia. Arch Neurol 1964;11:114-124
30. Howard JR JF, Duane DD, Lambert EH, Daube JR. Alternate day prednisone: preliminary report of a double-blind controlled study. Ann NY Acad Sci 1976;274:596-607
31. Lindberg C, Andersen O, Lefvert AK. Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study. Acta Neurol Scand 1998;97:370-373 (Pubitemid 28275908)
32. Zhang J, Wu H. Effectiveness of steroid treatment in juvenile myasthenia gravis. Chin J Ped 1998;36:612-614
33. Simon HE. Myasthenia gravis: effect of treatment with anterior pituitary extract. JAMA 1935;104:2065-2066
34. Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 1984;15:291-298 (Pubitemid 14164748)
35. Sghirlanzoni A, Peluchetti D, Mantegazza R, et al. Myasthenia gravis: prolonged treatment with steroids. Neurology 1984;34:170-174 (Pubitemid 14185359)
36. Cosi V, Citterio A, Lombardi M, et al. Effectiveness of steroid treatment in myasthenia gravis: a retrospective study. Acta Neurol Scand 1991;84:33-39
37. Evoli A, Batocchi AP, Palmisani MT, et al. Long term results of corticosteroid therapy in patients with myasthenia gravis. Eur Neurol 1992;32:37-43
38. Bu B, Yang M, Xu J, et al. A prospective study of effectiveness and safety of long-term prednisone therapy in patients with myasthenia gravis. Chin J Neurol 2000;33:28-31 (Pubitemid 30167573)
39. Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld R. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev 2005;(2) • An extraordinary revision of corticoids in MG
40. Sathasivam S. Steroids and immunosuppressant drugs in myasthenia gravis. Nat Clin Pract Neurol 2008;2008:317-327 (Pubitemid 351803614)
41. Cara CJ, Pena AS, Sans M, et al. Reviewing the mechanism of action of thiopurine drugs: towards a new paradigm in clinical practice. Med Sci Monit 2004;10:247-254 (Pubitemid 39546047)
42. Ferrero S, Esposito F, Biamonti M, et al. Myasthenia gravis during pregnancy. Expert Rev Neurother 2008;8:979-988 (Pubitemid 351872601)
43. Gajdos P. Myasthenia gravis clinical study group. A randomised clinical trial comparing prednisolone and azathioprine in myasthenia gravis. Results of a second interim analysis. J Neurol Neurosurg Psychiatry 1993;56:1157-63 • A randomized clinical trial comparing azathioprine+prednisone versus prednisone
44. Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 1998;50:1778-83 • A randomized double blind clinical trial comparing azathioprine + prednisone vs prednisone alone. (Pubitemid 28283251)
45. Delwaide PJ, Salmon J, Van Cauwenberge H. Preliminary observations of the treatment of myasthenia gravis by azathioprine. Acta Neurol Psychiatr Belg 1964;67:701-712
46. Matell G, Bergström K, Franksson C, et al. Effects of some immunosuppressive procedures in myasthenia gravis. Ann NY Acad Sci 1976;274:659-676
47. Witte AS, Cornblath DR, Parry GJ, et al. Azathioprine in the treatment of myasthenia gravis. Ann Neurol 1984;15:602-605 (Pubitemid 14124616)
48. Hohlfeld R, Toyka KV, Besinger UA, et al. Myasthenia gravis: reactivation of clinical disease and autoimmune factors after discontinuation of long-term azathioprine. Ann Neurol 1985;17:238-242 (Pubitemid 15136597)
49. Kuks JBM, Djojoatmodjo S, Oosterhuis HJ. Azathioprine in myasthenia gravis: observations in 41 patients and a review of literature. Neuromuscul Disord 1991;1:423-431
50. Mantegazza R, Antozzi C, Peluchetti D, et al. Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J Neurol 1988;235:449-453 (Pubitemid 18262976)
51. Rezzani R. Cyclosporine A and adverse effects on organs: histochemical studies. Prog Histochem Cytochem 2004;39(2):85-128
52. Busauschina A, Schnuelle P, Van der Woude FJ. Cyclosporine nephrotoxicity. Transplant Proc 2004;36:229S-33S (Pubitemid 38373867)
53. Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl Int 2000;13(5):313-326 (Pubitemid 30757147)
54. Tindall RS, Rollins JA, Phillips JT, et al. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 1987;316(12):719-24 • Double blind randomized trial demonstrating better results of patients treated with ciclosporin + prednisone than those treated with prednisone alone.
55. Tindall RS, Phillips JT, Rollins JA, et al. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann NY Acad Sci 1993;681:539-551 (Pubitemid 23233874)
56. Goulon M, Elkharrat D, Lokiec F, Gajdos P. Results of a one-year open trial of cyclosporine in ten patients with severe myasthenia gravis. Transplant Proc 1988;20(3 Suppl 4):211-217 (Pubitemid 18158707)
57. Bonifati DM, Angelini C. Long-term cyclosporine treatment in a group of severe myasthenia gravis patients. J Neurol 1997;244:542-547 (Pubitemid 27464098)
58. Lavrnic D, Vujic A, Rakocevic-Stojanovic V, et al. Cyclosporine in the treatment of myasthenia gravis. Acta Neurol Scand 2005;111:247-252 (Pubitemid 40380460)
59. Nagane Y, Utsugisawa K, Obara D, et al. Efficacy of low-dose FK506 in the treatment of myasthenia gravis: a randomized pilot study. Eur Neurol 2005;53:146-50 • The only randomized study up to date performed with tacrolimus. (Pubitemid 40864306)
60. Konishi T, Yoshiyama Y, Takamori M, et al. Clinical study of FK506 in patients with myasthenia gravis. Muscle Nerve 2003;28:570-574 (Pubitemid 37339910)
61. Konishi T, Yoshiyama Y, Takamori M, Saida T. Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus). J Neurol Neurosurg Psychiatry 2005;76:448-450 (Pubitemid 40299146)
62. Kawaguchi N, Yoshiyama Y, Nemoto Y, et al. Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis. Curr Med Res Opin 2004;20:1269-1273 (Pubitemid 39120791)
63. Ponseti JM, Azam J, Fort JM, et al. Long-term results of tacrolimus in cyclosporine- and prednisolone-dependent myasthenia gravis. Neurology 2005;64:1641-1643 (Pubitemid 40617711)
64. Allison C, Euqui EM. Mycophenolate mofetil and its mechanism of action. Immunopharmacology 2000;47:85-118 (Pubitemid 30394534)
65. Sieb JP. Myasthenia gravis: emerging new therapy options. Curr Opin Pharmacol 2005;5:303-307 (Pubitemid 40674254)
66. Meriggioli MN, Rowin J, Richman JG, Leurgans S. Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study. Ann NY Acad Sci 2003;998:494-499 (Pubitemid 37194203)
67. Sanders DB, Hart IK, Mantegazza R, et al. An international phase III, randomized trial of mycophenolate mofetil for myasthenia gravis. Neurology 2008;71:400-6 • An international randomized double bind trial studying the effectiveness of mycophenolate+predinose in MG patients.
68. Group MS. A trial of mycophenolate mofetil with prednisone as initial imunotherapy in myasthenia gravis. Neurology 2008;71:394-9 • An international randomized double bind trial studying the efectiveness of mycophenolate+predinose in MG patients.
69. Cos L, Mankodi AK, Tawil T, Thornton CA. Mycophenolate mofetil (MyM) is safe and well tolerated in myasthenia gravis (MG). Neurology54(Suppl 3):A137
70. Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 2001;56:97-99 (Pubitemid 32059659)
71. Meriggioli MN, Ciafaloni E, Al-Hayk KA, et al. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 2003;61:1438-1440 (Pubitemid 37463389)
72. De Feo LG, Schottlender J, Martelli NA, Molfino NA. Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis. Muscle Nerve 2002;26:31-6 • A randomized trial comparing cyclophosphamide + prednisone versus prednisone alone.
73. Perez MC, Buot WL, Mercado-Danguilan C, et al. Stable remissions in myasthenia gravis. Neurology 1981;31:32-37 (Pubitemid 11217450)
74. Drachman DB, Jones RJ, Brodsky RA. Treatment of refractory myasthenia gravis: 'rebooting' with high-dose cyclophosphamide. Ann Neurol 2003;53:29-34 •• This report introduces for the first time the concept of treatment with high doses of cyclophosphamide for resistant MG.
75. Drachman DB, Adams RN, Hu R, et al. Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis. Ann NY Acad Sci 2008;1132:305-314 (Pubitemid 351841373)
76. Hilton-Jones D. When the patient fails to respond to treatment : myasthenia gravis. Pract Neurol 2007;7:405-411 (Pubitemid 350237718)
77. Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Trasnplant 2006;65:859-866 (Pubitemid 44356635)
78. Harris HE. Progressive multifocal leucoencephalopathy in a patient with systemic lupus erythematosus treated with rituximab. Rheumatology (Oxford) 2008;47:224-225 (Pubitemid 351168240)
79. Hain B, Jordan K, Deschauer M, Zierz S. Successful treatment of MuSK antibody-positive Myasthenia Gravis with rituximab. Muscle Nerve 2006;33:575-580
80. Gajra A, Vajpayee N, Grethlein SJ. Response of myasthenia gravis to rituximab in a patient with non-hodgkin lymphoma. Am J Hematol 2004;77:196-197 (Pubitemid 39281869)
81. Diaz-Manera JA, Rojas-Garcia R, Gallardo E, et al. Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and morvan syndrome. Nat Clin Pract Neurol 2007;3:405-410
82. Illa I, Diaz-Manera JA, Rojas-Garcia R, et al. Sustained response to rituximab in anti-AChR and MuSK positive myasthenia gravis patients. J Neuroimmunol 2008;15(201-202):90-4 • This papers demonstrates differences in the response to rituximab between Musk and AchR patients.
83. Gold R, Stangel M, Dalakas M. Drug Insight: the use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues. Nat Clin Pract Neurology 2006;3:36-44
84. Dalakas M. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 2004;291:2367-2375 (Pubitemid 38656304)
85. Dalakas M. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharm Therap 2004;102:177-193 (Pubitemid 38887692)
86. Lisak RP. Plasmaexchange in neurologic disease. Arch Neurol 1984;41:647-654
87. Lehmann HC, Hartung HP, Hetzel GR, et al. Plasma exchange in neuroimmunological disorders: part 1: rationale and treatment of inflammatory central nervous system disorders. Arch Neurol 2006;63(7):930-935 (Pubitemid 44036291)
88. Gajdos P, Chevret S, Clair B, et al. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol 1997;41:789-96 • Clinical trial comparing plasma exchange and inmunoglobulins in MG patients.
89. Qureshi AI, Choudhry MA, Akbar MS, et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 1999;52:629-32 • Another interesting randomized trial comparing PE and IvIg in MG patients.
90. Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 2007;68:837-841 (Pubitemid 46568535)
91. Perez Nellar J, Dominguez AM, Llorens-Figueroa JA, et al. A comparative study of intravenous immunoglobulin and plasmapheresis preoperatively in myasthenia. Rev Neurol 2001;33:413-416 (Pubitemid 33647440)
92. Richman DP, Agius MA. Treatment of autoimmune myasthenia gravis. Neurology 2003;61:1652-1661 (Pubitemid 38020807)
93. Achiron A, Barak Y, Miron S, Sarova-Pinhas I. Immunoglobulin treatment in refractory Myasthenia gravis. Muscle Nerve 2000;23:551-555 (Pubitemid 30164781)
94. Gajdos P, Chevret S, Toyka KV. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2008, Issue1. Art. No.: CD002277. DOI: 10.1002/14651858.CD002277.pub3 • A complete review about the use of inmunoglobulins for MG patients.
95. Newson-Davis J, Vincent A, Wilson SG, et al. Plasmapheresis for myasthenia gravis. N Engl J Med 1978;298:456-457 (Pubitemid 8291368)
96. Pinching AJ, Peters DK, Newson-Davis J. Remission of myasthenia gravis following plasma exchange. Lancet 1976;2(8000):1373-1376 (Pubitemid 8004494)
97. Behan PO, Shakir RA, Simpson JA, et al. Plasma exchange combined with immunosuppressive therapy in myasthenia gravis. Lancet 1979;2:438-440 (Pubitemid 9250401)
98. Skeie GO, Apostolski S, Evoli A, et al. EFNS task force article: guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2006;13:691-9 •• Official guidelines of the EFNS, recommendations for treatment Mg patients.
99. Hart IK, Sathasivam S, Sharshar T. Immunosuppressive agents for myasthenia gravis. Cochrane Database Syst Rev 2007; Issue 4. Art. No:CD005224. DOI: 10.1002/14651858.CD005224.pub2 • An interesting paper reviewing the use of inmunosuppressors in MG patients.
100. Romi F, Skeie GO, Gilhus NE, Aarli JA. Striational antibodies in myasthenia gravis: reactivity and possible clinical significance. Arch Neurol 2005;62:442-446 (Pubitemid 40349480)
101. Davenport E, Malthaner RA. The role of surgery in the management of thymoma: a systematic review. Ann Thor Surg 2008;86:673-684 (Pubitemid 351978021)
102. Evoli A, Minisci C, Di Schino C, et al. Thymoma in patients with MG: characteristics and long-term outcome. Neurology 2002;59:1844-1850 (Pubitemid 36076553)
103. Kuppersmith MJ, Ying G. Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment. Br J Opthamol 2005;89:1330-1334 (Pubitemid 41638875)
104. Luchanok U, Kaminski HJ. Ocular myasthenia: diagnostic and treatment recommendations and the evidence base. Curr Opin Neurol 2008;21:8-15
105. Chan JW. Mycophenolate mofetil for ocular myasthenia. J Neurol 2008;255:510-513
106. Seybold ME, Drachman DB. Gradually increasing doses of prednisone in myasthenia gravis reducing the hazards of treatment. N Engl J Med 1974;290:81-84
107. Illa I. IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status. J Neurol 2005;252(Suppl 1):14-8 • A review of PE and IvIg in MG, Eaton Lambert disease and inflammatory myopathies.
108. Elovaara I, Apostolski S, van Doorn P, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS Task Force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 2008;15:893-908 • The official EFNS guidelines about the treatment of neurological disorders with IvIg.
109. Flacke W. Treatment of myasthenia gravis. N Engl J Med1973;288:27-31